Mercia’s Life Sciences helping the COVID-19 fight

Life sciences is one of Mercia’s areas of focus and investment expertise.

Mercia’s investment track record in the life sciences sector stretches back over 15 years. Today, Mercia manages a portfolio of over 400 businesses through its venture capital, private equity and debt managed funds, of which c 10% by number are in the life sciences sector. . It is notable that all seven life science investments in Mercia’s top 20 holdings originated through its managed funds.

Within the Mercia senior management team, Dr Mark Payton, Peter Dines and Dr Mark Wyatt, all have industry expertise in the sector as well as a long-term investment track record. With over 40 life sciences companies in the group, Mercia also has access to a network of non-executive directors, each a source of potential deal flow and sector contacts.

In association with Edison, watch this fascinating video In this interview with Dr. Mark Payton (CEO), Peter Dines (COO and previous head of life sciences) and Dr Mark Wyatt (investment director) as they discuss Mercia’s approach to investment in the life sciences sector, the impact of COVID-19 and what this might mean for Mercia’s future investment strategy in life sciences.